APA (7th ed.) Citation

M, K., RG, B., M, F., SP, I., MJ, L., PJ, B., . . . JM, V. (2022). Phase 1 trial of carfilzomib in relapsed/refractory peripheral T-cell lymphoma. Annals of hematology, 101(2), 335. https://doi.org/10.1007/s00277-021-04692-9

Chicago Style (17th ed.) Citation

M, Krishnan, et al. "Phase 1 Trial of Carfilzomib in Relapsed/refractory Peripheral T-cell Lymphoma." Annals of Hematology 101, no. 2 (2022): 335. https://doi.org/10.1007/s00277-021-04692-9.

MLA (9th ed.) Citation

M, Krishnan, et al. "Phase 1 Trial of Carfilzomib in Relapsed/refractory Peripheral T-cell Lymphoma." Annals of Hematology, vol. 101, no. 2, 2022, p. 335, https://doi.org/10.1007/s00277-021-04692-9.